Oncolytic viruses (OVs) are emerging as powerful new therapeutic agents in cancer treatment, employing nature’s own agents to find and destroy malignant cells. After talimogene laherparepvec (T-Vec), the first OV, obtaining US Food and Drug Administration approval, more and more attention in OVs has been paid. Recent advances in viral retargeting, genetic editing, tracking strategies and OV-based gene therapy have the potential to broaden the applications of OV in cancer treatment. Thus, OV-based cancer therapy is becoming more popular for scientists, clinicians, and the public. So far, numerous OVs are being developed pre-clinically and clinically against many kinds of cancers, such as melanoma, pancreatic, breast cancers, glioblastoma, rectal cancer, lung cancer, pancreatic and hepatocellular carcinomas, etc. yaba-like disease virus https://www.creative-biolabs.c....om/oncolytic-virus/a
